Active mutations of FGFR2 or FGFR3 are common in various cancers [20], whereas the oncogenic impetus of FGFR1 results mainly from either gene amplification or overexpression of wild-type receptor [21–23]. This evidence concerns the gene FGFR1 and cancer.